ArticleAbdominal radiology (New York)2026
Clinical and imaging comparison of primary liver carcinosarcoma and sarcomatoid carcinoma.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical features and prognostic factors for spinal metastasis from sarcomatoid carcinoma: identifying candidates suitable for surgical intervention.BMC musculoskeletal disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePrimary liver carcinosarcoma (CS) and sarcomatoid carcinoma (SC) are rare malignant tumors of the liver. Although the two tumors often overlap in clinical and imaging manifestations, there are currently no reports comparing the imaging features of these two tumors. Our study aims to compare the clinical characteristics and imaging features of these two tumors to further describe their distinct features, thereby enhancing understanding and diagnostic accuracy.
methodsA retrospective analysis was conducted on the clinical and imaging data of 17 patients with CS and 27 patients with SC diagnosed by surgical or needle biopsy between September 2010 and December 2024 at our hospital. The data were summarized and statistically analyzed.
resultsBoth groups were predominantly male, with a lower mean age (56.65 ± 11.82) in the CS group compared to the SC group (64.93 ± 8.15) (P = 0.01). Compared to the SC group, the CS group more commonly presented with hepatitis B, cirrhosis, and elevated AFP levels. Both groups were more commonly located in the right hepatic lobe, with larger tumors that were often solitary, irregularly shaped, and lobulated. Most tumors exhibited necrosis and hemorrhage. Calcification was observed in two cases in the CS group on CT scans. The tumor margins were predominantly indistinct, and the majority of tumors did not show a capsule. Approximately half of the patients in the SC group had lymph node involvement, which was significantly higher than in the CS group (P = 0.023). After contrast enhancement, all cases in both groups showed heterogeneous enhancement in the arterial phase. Regarding enhancement distribution, the CS group more commonly exhibited enhancement at the margins and in the solid components, while most cases in the SC group showed enhancement at the margins and in the septa. In terms of dynamic enhancement patterns, the CS group more commonly exhibited partial or complete regression in the delayed phase, while the SC group more commonly exhibited progressive or persistent enhancement in the delayed phase, with statistical significance (P = 0.042).
conclusionPatients in the SC group had significantly higher age and lymph node involvement than those in the CS group. In terms of tumor enhancement patterns, the CS group primarily exhibited delayed-phase regression or partial regression, while the SC group primarily exhibited delayed-phase persistent or progressive enhancement.
Indexed as
Identifiers
40848125What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.